KRYS - חוב כולל להון Krystal Biotech Corp.

This chart of the current share price of Krystal Biotech, Inc. (KRYS) demonstrates a debt-to-equity ratio of 0.01. Krystal Biotech, Inc. (KRYS) possesses exceptional pricing power due to its unique local gene delivery method. Effective collaboration with external contractors ensures stable product output. However, business success relies on test results, insurance company recognition, and the patent purity of its developments.

The total debt-to-equity ratio measures the extent to which business financing relies on borrowed funds relative to equity, reflecting the company's financial stability. By analyzing this total debt/equity chart, an investor can see the impact of share price on leverage, which is critically important for Krystal Biotech, Inc. (KRYS) given the capital-intensive development of autonomous ultra-low temperature logistics systems for gene therapies.